Scott White

Scientus is a vertically-integrated biopharmaceutical firm that is more than the sum of its parts. Through HydRx Farms Ltd., we are a Licensed Dealer under the Narcotics Control Regulations of Canada with a focus on developing and commercializing pharmaceutical-grade cannabinoid derivative products. As one of a limited number of Canadian Licensed Dealers able to handle cannabis, Scientus has the ability to wholesale buy, process and sell cannabinoid derivatives from and to Licensed Producers, as well as to export and import to international markets. On the strength of our patent-pending extraction and processing methods, Scientus posseses the technology to produce continuous, consistent batch profiles. This is a key criteria in formulating pharma-grade derivative products. Our products can be dispensed in a multitude of dosing forms, all providing standard measured doses for the reliable and consistent delivery of therapeutic formulations. All things considered, we are remarkably well-positioned to both anticipate and then lead the fast-track from research to market.

Scientus is a vertically-integrated biopharmaceutical firm that is more than the sum of its parts. Through HydRx Farms Ltd., we are a Licensed Dealer under the Narcotics Control Regulations of Canada with a focus on developing and commercializing pharmaceutical-grade cannabinoid derivative products. As one of a limited number of Canadian Licensed Dealers able to handle cannabis, Scientus has the ability to wholesale buy, process and sell cannabinoid derivatives from and to Licensed Producers, as well as to export and import to international markets. On the strength of our patent-pending extraction and processing methods, Scientus posseses the technology to produce continuous, consistent batch profiles. This is a key criteria in formulating pharma-grade derivative products. Our products can be dispensed in a multitude of dosing forms, all providing standard measured doses for the reliable and consistent delivery of therapeutic formulations. All things considered, we are remarkably well-positioned to both anticipate and then lead the fast-track from research to market.